Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia

Completed · Phase 2

Conditions studied: Anemia, Leukemia, Neutropenia, Thrombocytopenia

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as leridistim and filgrastim increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Randomized phase II trial to compare the effectiveness of leridistim with that of filgrastim to reduce side effects in older patients who are receiving cytarabine and daunorubicin for acute myeloid leukemia.

Key facts

Study ID
NCT00004215
Run by
Memorial Sloan Kettering Cancer Center
Starts
1999-08-01
Expected to finish
2000-08-01
Last updated by the study team
2013-06-19

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.